Syndax Reports Updated Positive Data From Phase 1/2 Combination Trials Of Revumenib

June 14, 2024 — 07:22 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Syndax Pharmaceuticals (SNDX) announced updated data from multiple combination trials of revumenib, the company's selective, small molecule menin inhibitor, in patients with acute leukemias. The company said the data continue to support revumenib's potential to enhance current standard of care agents.

"We are committed to advancing revumenib across a spectrum of acute leukemia patients. As we prepare for the expected near-term approval of revumenib in the relapsed or refractory setting, we look forward to providing additional clinical data as monotherapy and in combination to support treatment in various acute leukemia treatment settings where novel treatment options are urgently needed," said Neil Gallagher, President, Head of Research and Development at Syndax.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Syndax Reports Updated Positive Data From Phase 1/2 Combination Trials Of Revumenib

Tags

Latest Articles